1 Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao TongUniversity, Shanghai 200080, China
2 Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China
3 Shanghai Key Laboratory of Fundus Diseases, Shanghai 200080, China
Age-related macular degeneration (AMD) is one of the major causes of blindness around the world.Anti-vascular endothelial growth factor (anti-VEGF) therapy has become the first-line therapy for treating neovascular AMD (nAMD). Considering the burden of the high cost of anti-VEGF medicine, long-term and often lifelong repeated injections required of patients, it is important to understand the patterns of anti-VEGF therapy for nAMD patients in real-world settings, which will optimize the delivery of healthcare for nAMD patients, improve clinical pathways and may even help with decision-making in healthcare policy. Recently, data analysis studies on nAMD, based on electronic information platforms, have unveiled the epidemiology of nAMD in different countries and regions, the anti-VEGF therapy patterns in the real
world and the medical expenditure related to nAMD. This article reviews research progress in real-world studies on nAMD based on electronic information platforms.
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health, 2014, 2(2): e106-16. DOI: 10.1016/S2214-109X(13)70145-1.
Cheung CM, Wong TY. Treatment of age-related macularde generation. Lancet, 2013, 382(9900): 1230-1232. DOI:10.1016/S0140-6736(13)61580-9.
[4]
Brown DM, Michels M, Kaiser PK, et al, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year
results of the ANCHOR study. Ophthalmology, 2009, 116(1):57-65. DOI: 10.1016/j.ophtha.2008.10.018.
[5]
Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006, 355(14): 1419-1431. DOI:
10
1056/NEJMoa054481.
[6]
Singer MA, Awh CC, Sadda S, et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology,2012, 119(6): 1175-1183. DOI: 10.1016/j.ophtha.2011.12.016.
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med, 2016,375(23): 2293-2297. DOI: 10.1056/NEJMsb1609216.
Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: Standardization of disease classifications and anonymous record linkage. J Epidemiol, 2010, 20(5): 413-419.
[12]
Altman D, Frist WH. Medicare and medicaid at 50 years:Perspectives of beneficiaries, health care professionals and institutions, and policy makers. JAMA, 2015, 314(4): 384-395.
DOI: 10.1001/jama.2015.7811.
[13]
Adler-Milstein J, Holmgren AJ, Kralovec P, et al. Electronic health record adoption in US hospitals: The emergence of a digital "advanced use" divide. J Am Med Inform Assoc, 2017,
24
(6): 1142-1148. DOI: 10.1093/jamia/ocx080.
[14]
Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology, 2018,125(4): 522-528. DOI: 10.1016/j.ophtha.2017.10.010.
[15]
Ng WY, Cheung CM, Mathur R, et al. Trends in age-related macular degeneration management in Singapore. Optom Vis Sci,2014, 91(8): 872-877. DOI:10.1097/OPX.0000000000000283.
[16]
Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol, 2014, 158(3):537-543. DOI: 10.1016/j.ajo.2014.05.014.
[17]
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med, 2011, 364(20): 1897-1908. DOI: 10.1056/
NEJMoa1102673.
[18]
Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: Outcomes of a drug and
Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: Analysis of 284 380 medicare beneficiaries. Am J Ophthalmol, 2012, 153(6):1116-1124. DOI: 10.1016/j.ajo.2011.11.032.
[20]
Obeid A, Gao X, Ali FS, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol, 2018, 136(11): 1251-1259. DOI: 10.1001/jamaophthalmol.2018.3578.
[21]
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: Multicenter study of 92 976
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists
Day S, Acquah K, Lee PP, et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol, 2011, 152(6): 1014-1020. DOI: 10.1016/j.ajo.2011. 05.008.
[24]
Schmier JK, Covert DW, Lau EC. Patterns and costs associated with progression of age-related macular degeneration. Am J Ophthalmol, 2012, 154(4): 675-681. DOI: 10.1016/j.ajo.2012.04.017.
[25]
Brown MM, Brown GC, Lieske HB, et al. Societal costs associated with neovascular age-related macular degeneration in the United States. Retina, 2016, 36(2): 285-298. DOI: 10.1097/ IAE.0000000000000717.
[26]
Windsor MA, Sun SJJ, Frick KD, et al. Estimating public and patient savings from basic research―A study of optical coherence tomography in managing antiangiogenic therapy. Am
浙公网安备 33030202001892号